For some time the pros and cons of radiotherapy versus radical surgery for localised prostate cancer have been hotly debated. Both sides however agree that the results for patients with locally advanced disease are relatively dismal. Now evidence is accumulating that the combination of neoadjuvant hormonal ablation with external beam radiotherapy may provide some hope for these patients. In the Radiation Therapy Oncology Group 8610 trial 471 men were randomly assigned to external beam radiotherapy with or without androgen ablation, which was started 8 weeks before radiation and continued for a total of 16 weeks.
Despite this brief exposure to reduced androgen levels, at 5 years the men in the combined therapy group had better local control (54% vs. 15%) and were more likely to be free of disease (36% vs. 15%). However, so far they have no better survival than the men who received only radiotherapy (Zietman et el Urology 1997 49: 74±83S). Similar results have been recently reported by Bolla et al. (N Engl J Med 1997, 337: 295±300) . In this European study the men given combined treatment of androgen ablation and external beam radiotherapy had better local control (97% vs. 76%) freedom from disease (85% vs. 48%) and, in a ®nding unique to this study, improved overall survival (79% vs. 62%). Although there are some criticisms one could make of this study, and the results are still preliminary, it does seem that the combination of androgen ablation coupled with radiation therapy may improve the outlook of those presenting with locally advanced prostate cancer.
Dr Patrick Walsh visits Ireland
Patrick Walsh, the originator of the nerve sparing radical prostatectomy procedure, visited Galway in the west of Ireland last month. Speaking at a joint meeting of British and Irish urologists he reviewed the evidence for the location of the hereditary prostate cancer (HPC) gene on chromosome 1q (Smith J. et al Science 1996 , 274:1301± 1306 . He also presented the case for early diagnosis and treatment, especially in those with a positive family history. He pointed out that in Scandinavia, where watchful waiting is generally advised for patients with localised disease, the mortality from prostate cancer is the highest in the world.
alpha-reductase inhibitor therapy reduces the complications of BPH
Benign prostatic hyperplasia (BPH) af¯icts the majority of men beyond middle age. Until recently treatment has been aimed at improving quality of life by improving lower urinary tract symptoms. At the recent meeting of the Societe Â D'Urologie Internationale (SIU) Dr John McConnell provided further data from the USA to con-®rm the ®ndings of Andersen et al (Urology 1997 49: 839± 845) that ®nasteride reduces the risk of acute urinary retention by 54% and the need for surgery by over 30%. This new data suggests that urologists, like their colleagues in cardiovascular medicine need to change their mindset and think in terms of prevention rather than cure.
Prostate Cancer Charitable Trust Award
The Prostate Cancer Charitable Trust was set up 3 years ago by millionaire philanthropist Clive Bourne in conjunction with Jean Jacques Robot.
This year the Trust awarded nearly one third of a million pounds to Dr Ros Eeles at the Royal Marsden Hospital, London, to further her important collaborative research into familial prostate cancer at the Imperial Cancer Research Fund laboratories.
Hope of a new prostate cancer vaccine
Dendritic Cells (DC) have been shown to be the most effective antigen presenting cells capable of delivering and targeting cancer antigens for T cell recognition. The laboratory of Drs. Benjamin Tjoa and Gerald Murphy, at Northwest Hospital, Seattle, WA, utilized DC, isolated and cultured from patient peripheral blood, as antigen presenting cells, and PSMA (prostate speci®c membrane antigen) as antigen for the development of a prostate cancer vaccine. PSMA is a membrane-bound protein expressed by prostate epithelial cells. Preclinical studies showed that patients' DC can present HLA-speci®c PSMA peptides, resulting in T cell activation in vitro.
In a recently completed Phase I clinical trial, 51 patients were divided into 5 treatment groups receiving 4 or 5 infusions of either: HLA-A0201-speci®c PSMA peptides (PSM-P1 or, -P2) only, autologous DC only, and autologous DC pulsed with PSM-P1, or -P2. No signi®cant acute or chronic toxicity was observed after completion of all scheduled infusions, and 7 partial responders were iden-ti®ed according to National Prostate Cancer Project criteria (plus 50% decrease in PSA). A phase II study involving 73 participants currently is being conducted at Northwest Hospital, Seattle, WA. Participants in this study include 41 patients with hormone refractory clinical progressive prostate cancer and 32 patients with locally recurrently prostate cancer. All participants receive a total of six infusions of autologous DC pulsed with a PSM-P1 and -P2 cocktail at six week intervals. In addition, half of the participants in each group receive subcutaneous injection of GM-CSF as a systemic adjuvant with each dendritic cell infusion.
These novel studies demonstrate the excellent potential of DC as a component of the new generation of cancer vaccines.
What's in the pipeline?
Traditionally prostate disease has been a Cinderella subject with far more attention being paid to other disease areas such as lung, colon and breast.
With the greying of the baby boomers however and the demographic shift towards increasing longevity the prostate is at last receiving some attention. Table 1 lists 182 drugs for prostatic disease which are either available or in development. It is to be hoped that these novel compounds will provide important breakthroughs to improve both overall survival and quality of life for the very many sufferers of prostatic diseases. 
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